The shareholder class action firm said Indivior investors are set to own about 56.5% of the combined company when the proposed transaction closes.
Monteverde & Associates PC said it is investigating Indivior Pharmaceuticals, Inc. in connection with its proposed merger with Supernus Pharmaceuticals, Inc., framing the review around whether the deal is fair to Indivior shareholders. The firm said Indivior investors would own approximately 56.5% of the combined company upon closing. The announcement was issued from New York on Aug. 3, 2026 as attorney advertising and invited shareholders to seek more information or contact Juan Monteverde, Esq. directly.